596 filings
6-K
IMMP
Immutep Limited
15 May 24
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003
9:15pm
6-K
IMMP
Immutep Limited
2 May 24
Positive Initial Clinical Data Reported from Immutep’s Efti
6:16pm
6-K
IMMP
Immutep Limited
30 Apr 24
Immutep Quarterly Activities Report & Appendix 4C
6:05am
6-K
IMMP
Immutep Limited
24 Apr 24
Immutep Announces Positive Preliminary Topline Results from
5:40pm
6-K
IMMP
Immutep Limited
18 Apr 24
Immutep Appoints Leading Research Institute to Conduct
6:57pm
6-K
uot69asifwc872cx
6 Mar 24
Immutep Announces First Clinical Data from 90mg Dosing of Efti
12:00am
6-K
k2ptgncl4iww id9
29 Feb 24
Half-Year Financial Report
6:08am
6-K
78csa pbcti
30 Jan 24
Immutep Quarterly Activities Report & Appendix 4C
4:01pm
6-K
1negker qo8p5ndzsyqh
21 Dec 23
Immutep Receives Constructive Regulatory Feedback on TACTI-004
6:06am
6-K
97b93
7 Dec 23
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
8:36pm
6-K
sir3fa a2y1euag
9 Nov 23
Current report (foreign)
5:01pm
6-K
iec2ae 68
6 Nov 23
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
4:42pm
6-K
fkb erf4us
3 Nov 23
Immutep Announces New Biomarker Data from TACTI-002 Phase II
6:06am
6-K
p1ozo0 syrzs0zojypc
31 Oct 23
Immutep Quarterly Activities Report & Appendix 4C
6:09pm
6-K
18b4a9s dwlsc
25 Oct 23
Immutep receives ~A$1.13 million R&D Tax Incentive
6:07am
6-K
cpp pc3yl
24 Oct 23
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial
7:06pm
6-K
2w416 c5cmm9i
24 Oct 23
Current report (foreign)
6:35am
6-K
ehk3fncr4pb
16 Oct 23
Immutep Announces Publication of Abstracts at ESMO Congress 2023
7:23pm
6-K
3lwlbt
21 Sep 23
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
6:05am
6-K
ueqsupofh49ebv6rhu
2 Aug 23
Immutep Receives Positive Scientific Advice from European Medicines Agency
12:00am